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impressive decrease in Gd-enhancing lesions
Anne-Hilde Muris1,2,5*, Linda Rolf1,2, Jan Damoiseaux3, Ellen Koeman4 and Raymond Hupperts1,2Abstract
Background: Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple
sclerosis (RRMS), as is natalizumab. Fingolimod decreases annual relapse rates and gadolinium enhancing lesions on
MRI as compared to either interferon beta (IFNβ) or placebo. The effect of fingolimod on MRI outcomes compared
to natalizumab treatment has not been investigated in (head to head) clinical trials. Clinical experience with
natalizumab is much more extended and in general practice often preferred.
Case presentation: This case describes a 31-year old woman with RRMS, who experienced severe side effects on
natalizumab. After a voluntary four months treatment free period, a severe relapse appeared which was treated with
prednisone and plasmapheresis; thereafter fingolimod was initiated. In the following months MRI signs improved
spectacularly.
Conclusion: This case suggests that fingolimod might be a good alternative for natalizumab, especially for use in
RRMS patients, with highly active, advanced disease, when natalizumab treatment is stopped due to side effects or
even after a severe relapse.
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Fingolimod (FTY720, Gilenya®, Novartis Pharma AG,
Basel, Switzerland) is like natalizumab (Tysabri®, Biogen
Idec Inc, Weston, MA, USA) a single disease modifying
therapy (DMT) in highly active relapsing remitting mul-
tiple sclerosis (RRMS) patients. Fingolimod is registered
in 80 countries across the world. In some countries, like
the USA, Switzerland, Australia and Russia, fingolimod
is approved as a first line treatment while in Europe and
Canada fingolimod is a second line therapy especially for
those patients who are non-respondent to at least one
other DMT like interferon beta (IFNβ) or glatiramer
acetate (GA) or who have rapidly evolving MS [1-3].
Fingolimod is an oral sphingosine 1-phosphate recep-
tor modulator and acts as a functional antagonist redu-
cing the amount of circulating pathogenic lymphocytes* Correspondence: a.muris@maastrichtuniversity.nl
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cells to egress from the lymph nodes. It might also play
a role in the neuroprotection of the central nervous sys-
tem (CNS) [4]. Phase II and phase III studies with fingo-
limod have shown a decrease in annual relapse rate, as
well as a reasonable decline in gadolinium (Gd) enhan-
cing lesions on MRI, both in number and volume, after
up to 36 months of fingolimod treatment compared to
either first line treatment with IFNβ or placebo [5-7].
The effect of fingolimod compared to natalizumab
treatment has never been investigated in a head-to-head
clinical trial. However, natalizumab was approved ap-
proximately five years before fingolimod and therefore
the clinical experience with natalizumab is much more
extended and in general practice often preferred [1,2,8].
When natalizumab is discontinued, because of various
reasons, a switch to fingolimod is an obvious next step.
However, reactivation of disease in patients switching
from natalizumab to fingolimod is reported in a consid-
erable proportion of patients [9-11].
Here we describe a case of a patient who suffered from
highly active RRMS which was treated with fingolimodtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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natalizumab and a treatment free interval of four
months. We consider this case as a striking example
of the positive effect that fingolimod treatment may
have especially on MRI outcome, even after successful
natalizumab treatment.
Case presentation
A 31-year old woman was diagnosed with RRMS at the
age of 25. Three years before diagnosis she presented
with a first event of one-sided optic neuritis. She did not
have any further medical history.
Several first line treatments, i.e. GA and IFNβ-1b had
insufficient effect: exacerbation rate remained high
and MRI showed a slight increase in lesion number
(Figure 1A). While second line therapy was not indi-
cated because of patient’s desire to become pregnant,
treatment with intravenous immunoglobulins was ini-
tiated. Immunoglobulins are not a registered therapy
in MS, but can be used off-label if no other options are
available [12]. However, relapse rate remained high
and one and a half year after IFNβ-1b was stopped, she
was still in a moderate clinical condition and MRI
showed multiple new T1 Gd enhancing lesions. Therefore,
after a third relapse during immunoglobulin treatment,
treatment with natalizumab was initiated. The one re-
lapse she experienced during the natalizumab treat-
ment was in an early phase, and therefore might have
been still the result of the highly active MS before the
effects of natalizumab. MRI, 11 months after initiation
of natalizumab, showed a slight increase in white mat-
ter lesions on T2 (FLAIR) MRI without any T1 Gd en-
hancing lesions (Figure 1B). At a later stage the patient
was tested positive for anti-JC virus antibodies and suf-
fered from severe side effects, like frequent urinary
tract infections and herpes zoster infections. All to-
gether this made discontinuation of natalizumab after
20 months of treatment inevitable. After a voluntary
treatment-free interval of four months, she had a ser-
ious relapse with right sided hemiplegia, problems with
coordination, ataxia and dizziness, for which an acute
admission into the hospital was needed. Tests for JC-virus
DNA in CSF were negative, excluding progressive multi-
focal leucoencephalopathy (PML), but MRI of the brain
showed an increased number of T2 lesions on conven-
tional T2 MRI, an increased volume on T2 FLAIR MRI
and an increased number of T1 Gd enhancing lesions
throughout the white matter (Figure 1B). After plasma-
pheresis and methylprednisolone (MP) treatment, con-
trol MRI showed only minor improvement. At that time
fingolimod treatment was started. From that moment
on the patient’s condition gradually improved and she
remained relapse-free. Moreover, most recent MRI of
the brain (8 months after the initiation of fingolimod)showed a striking decrease in the number of T1 Gd en-
hancing white matter lesions (Figure 1A and B), without
any new Gd enhancing lesions.
Natalizumab and fingolimod both are registered im-
munomodulatory therapies in RRMS, currently known
to have comparable effectiveness. Natalizumab, in gen-
eral practice frequently used, results in clinical and
MRI stabilization, or even improvement [13]. However,
in the long term, natalizumab treatment has some
shortcomings. Side effects like frequent urinary tract
infections or herpes infections can occur. Also the in-
creasing risk of getting PML in anti-JC virus antibody
positive patients can lead to discontinuation of treat-
ment. Fingolimod, with a different mechanism of action
but shown to be also highly effective in reducing relapse
rate in RRMS, might therefore be a good alternative for
natalizumab [1,14].
A potential risk of natalizumab discontinuation is the
risk of reactivation of disease, as is also described in
our case presentation. Radiological and clinical re-
bound, in which disease activity increases to levels
even higher than baseline, has been described between
1 and 6 months after discontinuation of natalizumab
[15]. However, in most cases disease activity returns to
baseline with a peak four months after withdrawal [16].
Fingolimod has been described to potentially mitigate
the reactivation of disease after withdrawal of natali-
zumab [17]. However, severe relapses in the first
months after switching from natalizumab to fingoli-
mod have also been reported [9-11]. These differences
in outcome of fingolimod treatment used to overcome
disease reactivation might be due to differences in
duration of the wash out period of natalizumab. The
wash out period between natalizumab and fingolimod
is considered not to exceed two or three months
[18,19]. On the other hand, recently an observational
study showed that relapses after switching from nata-
lizumab to fingolimod occurred independently of the
wash-out period [20].
In this case presentation, fingolimod was not used
to prevent a rebound effect or reactivation of disease
after discontinuation of natalizumab. Instead, after
natalizumab withdrawal initially the patient did not
receive any immunomodulatory medication. Only
after the severe relapse, four months later, fingolimod
was started. Afterwards, the patient stabilized clinic-
ally and T1 Gd enhancing lesions decreased spec-
tacularly with only one persistent Gd lesion and no
new Gd enhancing lesions after 8 months (Figure 1B).
Although, Gd enhancing lesions may become inactive
after 2–3 months, this decrease from 54 T1 Gd en-
hancing lesions to only one persistent is conspicuous
and a treatment effect of fingolimod therefore almost
undeniably.
BA
Figure 1 Schematic overview of disease course. (A) Disease course from diagnosis, including (B) quantification of MRI (T1gado, T2 and T2 FLAIR)
before and after start of fingolimod. Shown are patient’s treatment regime, relapses (in closed dots when treated with methylprednisolone (MP), in
open dots when untreated), time points of all MRI and EDSS scores. The lower part of the figure (B) shows the last five, most relevant, subsequent
T2 FLAIR and T1 Gd MRI’s. T2 lesion count and lesion load (measured using conventional T2 MRI and FLAIR MRI) and T1 Gd lesion counts are shown.
T2 lesion count and lesion load were quantified by an expert reader in MIPAV (version 5.1.1, Center for Information Technology, Bethesda, Maryland).
At follow up visits subtracted images were used for MRI analyses. Total T2 lesion load at follow up was calculated as the lesion load at baseline (MRI 1)
plus negative and/or positive activity change. Time points of MRI in MS course: MRI 1 – before start of natalizumab treatment (during exacerbation).
MRI 2 – just after restart natalizumab treatment (remission). MRI 3 – during exacerbation 4 months after natalizumab discontinuation before
plasmapheresis. MRI 4 – during exacerbation 4 months after natalizumab discontinuation after plasmapheresis. MRI 5 – 8 months after start
of fingolimod (remission). Abbreviations: DMT: disease modifying therapy; EDSS: Expanded Disability Status Scale; FLAIR: Fluid Attenuation
Inversion Recovery.
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This case shows and confirms that fingolimod might be
radiologically and clinically as effective as and a good
alternative for natalizumab in highly active advanced
RRMS or possibly even in patients developing relaps-
ing progressive MS. Based on this case report one
might speculate fingolimod to be a good alternative fornatalizumab in anti JC virus positive patients. Moreover,
it might even be useful in the treatment regime of a MS
patient after a severe relapse.
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